

Supplementary table S1. Withdrawal analyses

| | 11 years' follow-up cohort - included (n = 120) A | 11 years' follow-up cohort - not included (n = 40) B | 11 years' prediction cohort - included (n = 96) C | 11 years' prediction cohort – not included (n = 64) D | P value A vs. B | P value C vs. D |
|--------------------------|--|---|--|---|--------------------|--------------------|
| Age (years) | 52.0 (42.5-60.1) | 54.7 (41.4-66.2) | 52.8 (43.1-60.6) | 52.7 (41.8-65.1) | 0.21 | 0.60 |
| Gender (% women) | 30 | 43 | 31 | 36 | 0.21 | 0.66 |
| Disease duration (years) | 0.27 (0.21-0.38) | 0.28 (0.22-0.42) | 0.27 (0.20-0.38) | 0.29 (0.22-0.39) | 0.57 | 0.37 |
| DAS28 (CRP based) | 5.4 (4.4-6.1) | 5.8 (5.2-6.4) | 5.4 (4.4-5.9) | 5.7 (4.9-6.4) | 0.03 | 0.04 |
| HAQ | 0.75 (0.375-1.375) | 1.125 (0.75-1.656) | 0.75 (0.375-1.375) | 1.125 (0.625-1.625) | 0.01 | 0.006 |
| Anti CCP (% positive) | 57 | 63 | 58 | 59 | 0.68 | 0.98 |
| IgM-RF (% positive) | 65 | 70 | 64 | 70 | 0.70 | 0.47 |
| Erosive disease (%) | 62 | 55 | 64 | 56 | 0.55 | 0.44 |
| TSS (median(IQR)) | 3 (0-8) | 2 (0-6) | 3(0-8) | 2 (0-6.5) | 0.52 | 0.26 |
| TSS (mean±SD) | 5.03±6.21 | 5.05±7.96 | 5.36±6.21 | 4.49±6.92 | 0.52 | 0.26 |